SUMMIT, N.J.--( / ) October 09, 2018 -- Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo.
In addition to achieving the primary endpoint, statistical significance was also met for the secondary endpoint of the whole body itch numeric rating scale (NRS) [defined as at least a 4-point reduction from baseline] at week 16 with OTEZLA versus placebo.
The safety profile was generally consistent with the known safety profile of OTEZLA, and no new safety signals were identified in the trial. Treatment-emergent adverse events that occurred in at least 5 percent of patients in either treatment group were diarrhea (30.5 percent for OTEZLA and 10.8 percent for placebo), nausea (21.5 percent and 5.9 percent, respectively), headache (11.5 percent and 4.9 percent) and vomiting (5.5 percent and 2.0 percent).
“The scalp is the most commonly affected area in moderate to severe plaque psoriasis, impacting up to 80 percent of patients,” said Terrie Curran, President, Celgene Inflammation and Immunology. “The area is difficult to treat with topical therapies, and clinical data from systemic therapies are limited. We are encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the OTEZLA label.”
STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of OTEZLA in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive OTEZLA 30 mg twice daily or placebo for the first 16 weeks.
About Plaque Psoriasis
Psoriasis affects 125 million people worldwide, including around 14 million people in Europe and 7.5 million people in the United States. It is a chronic and systemic inflammatory disorder, and is immune-mediated, meaning it is caused by an immune reaction in the body.
Psoriasis lesions can often be found on areas close to the joints such as the elbows and knees but can also appear on the scalp. Nail psoriasis affects up to 50 percent of people with psoriasis. Up to 84 percent of people with psoriasis experience itching, and over a third of patients cite itch as the most important factor contributing to their disease.
Around 75 percent of people living with psoriasis believe it has a negative impact on their quality of life, and 83 percent of patients with psoriasis actively conceal the visible signs of their disease.
About OTEZLA® (apremilast)
OTEZLA® (apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients is not well defined.
U.S. PRESCRIBING INFORMATION
OTEZLA® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
IMPORTANT SAFETY INFORMATION
OTEZLA® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation
Warnings and Precautions
Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of OTEZLA. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider OTEZLA dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
Depression: Carefully weigh the risks and benefits of treatment with OTEZLA for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on OTEZLA. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
Psoriasis: Treatment with OTEZLA is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo; Depression was reported as serious in 0.1% (1/1308) of patients exposed to OTEZLA, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on OTEZLA, compared to 0.2% (1/506) on placebo. One patient treated with OTEZLA attempted suicide; one patient on placebo committed suicide
Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of OTEZLA
Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with OTEZLA and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with OTEZLA compared to 1% (3/382) of patients treated with placebo
Drug Interactions: Apremilast exposure was decreased when OTEZLA was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of OTEZLA efficacy may occur. Concomitant use of OTEZLA with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended
Psoriasis: Adverse reactions reported in ≥5% of patients were (OTEZLA%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)
Use in Specific Populations
Pregnancy and Nursing Mothers: OTEZLA is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when OTEZLA is administered to a nursing woman
Renal Impairment: OTEZLA dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information
Please click here for Full Prescribing Information.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next?generation solutions in protein homeostasis, immuno?oncology, epigenetics, immunology and neuro?inflammation. For more information, please visit Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SECAUCUS, 인천유나이티드득점왕 SECAUCUS,J.--( / ) October 08, 2019 -- NTT (TOKYO:9432), a global technology and business solutions leader, and Major League Baseball (MLB) today successfully conducted 섹스중독 아즈사나가사와 a Proof of Concept (PoC) with NTT’s Ultra Reality Viewing technology (URV) 섹스중독 as part of their recently announced multi-year technology agreement making the Japan-based company 남방동홀덤대회 줄리아 an official MLB partner in the United States. This implementation verified the feasibility 남방동홀덤대회 허리디스크터짐 of a real-time super-high definition surround video fan experience event, a first for a live sporting event in the United States.
A key foundation of the 섹스중독 서울홀덤 partnership is a collaborative intent to create a new fan experience in the Smart World era. Ultra Reality Viewing was successfully proven at Game 앰카지노 A섹스중독 성기능장애 of the American League Division Series presented by Doosan between the Houston Astros and Tampa Bay Rays from Tropicana Field. In the ballpark, NTT installed multiple 4K cameras that transmitted high definition images (12K wide) in real time to a super-wide 남방동홀덤대회 젤크 screen (90.6 in x 469 in) with 6ch surround sound including original audio sauce to a viewing area set up at MLB Network’s studio in Secaucus, 섹스중독 남자조루 NJ. This URV technology created a uniquely 남방동홀덤대회 transformative sensation that put the remote viewer into the ballpark and its atmosphere live.
Enterprise Partners were invited to 남방동홀덤대회 홀덤머니상 this viewing event in order to increase the awareness for other 풀팟 Enterpriseuses of this Ultra Reality Viewing experience technology. 섹스중독 캐쉬홀덤 NTT and MLB will continue 남방동홀덤대회 to work toward expanding the use of URV Technology for new and 정선카지노 중고차 Enterprisefan experiences in 섹스중독 축구토토하는법 other events. 남방동홀덤대회 비뇨기과발기부전
Ultra Reality Viewing is NTT’s real-time super high-definition surround video synthesis 섹스비디오 Ultrathat combines multiple 4K camera images into a super-wide image such as 12K in 알바할래 Ultraand transmits them synchronously to remote locations. With the super high-definition surround videos which 섹스중독 cannot be captured by general cameras and audio technologies which enable original sounds to generate and transmit to remote location without loss and time difference and regenerate 남방동홀덤대회 토토배팅사이트 those certain sounds fields through the remote location, audiences can view sports or events content as if they were watching it live in the stadium, on the field or in the theatre. 캔디넷 Ultrais a proven solution based on NTT’s unique R&D technology, 섹스중독 런앤런 “Kirari!(*1).” It has been successfully implemented in Japan to enhance audience viewing and fan experiences with very positive results.
About 남방동홀덤대회 사설프로토 섹스중독 사설프로토 토렌트홀 About
Major League Baseball (MLB) is the most 남방동홀덤대회 축구화 historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Major League Baseball is the 토렌트홀 Majorsport in imax툰 MajorAmerica, and since 2004, MLB has enjoyed its best-attended seasons in the history of the 남방동홀덤대회 game. Led by Commissioner Robert D. Manfred, Jr., MLB currently features record levels of labor peace, competitive balance and industry revenues, as well as the most comprehensive drug-testing program in American professional sports. MLB remains committed to 남방동홀덤대회 약국판매 making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role FETISH Majorsociety and permeating every facet 섹스중독 야구토토결과 of baseball’s business, marketing and community relations endeavors. With the continued success of MLB Network and MLB digital platforms, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit
NTT 남방동홀덤대회 is a global technology and business solutions provider. We help clients grow their business and improve their competitive market position by delivering fully 마시타마히리 NTT하트사용방법 NTTincluding global 성인용품쇼핑몰사용후기 NTT남방동홀덤대회 축구핸디캡 cybersecurity, 섹스중독 축구경기분석 managed IT and applications, cloud and datacenter services combined with business consulting and deep industry expertise. As a top-five global technology and business services provider, NTT 섹스중독 발기부전상담 works with over 80 of the Global Fortune 100 남방동홀덤대회 축구승무패예상 companies and many thousands of other clients and communities to achieve their goals and contribute to a sustainable future. For more information on NTT, visit
View source version 섹스중독 on 남방동홀덤대회 발기링 세이프토토 ViewNewswire distributes your 섹스중독 정맥매복술 news 남방동홀덤대회 센돔구매 across every media channels through the industry’s 섹스중독 largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.